Ginkgo Bioworks Holdings, Inc. Class A (DNA)

In the past six months, Ginkgo Bioworks' stock (DNA) closed at $6.45 on April 10, 2026, which was 20.11% above its 52-week low. Over the past 52 weeks, the stock has traded between $5.37 and $17.58. In February 2026, the company reported a 24% decrease in total revenue for Q4 2025 and revealed a strategic pivot to focus on autonomous labs and divest its non-core biosecurity business. In March 2026, Ginkgo launched Ginkgo Cloud Lab, powered by autonomous lab infrastructure. In April 2026, the stock price has shown some fluctuations, with instances of falling below its 15-day moving average.

Ginkgo Bioworks has experienced a challenging demand environment, not directly linked to traditional seasonality but rather to broader market conditions and strategic shifts. The company continues to face weak demand, with funding for academic customers under pressure and elevated interest rates impacting its business. Its industrial and consumer businesses have been particularly hard hit. In response, Ginkgo is divesting its biosecurity business and focusing on autonomous labs to capitalize on the emerging opportunity for AI-enabled drug discovery.

Ginkgo Bioworks Holdings, Inc. is an American biotechnology company operating as a horizontal platform for cell programming, providing end-to-end services across various markets. The company uses genetic engineering to produce bacteria with industrial applications, aiming to reduce initial design costs in synthetic biology. It operates in the Healthcare sector and the Biotechnology and Life Sciences Tools and Services industries, divided into Cell Engineering and Biosecurity segments. The Cell Engineering segment provides biological R&D services, while the Biosecurity segment offers biomonitoring and bioinformatics support, though the biosecurity business is being divested.

Ginkgo Bioworks Holdings, Inc. was founded in Boston, Massachusetts, in 2008, where its headquarters are located. The company develops its cell programming platform in the United States, with facilities in Cambridge, Massachusetts, and West Sacramento, California, after acquiring Bayer's Biologics Research & Development site. The company has also mentioned international expansion for its biomonitoring and bioinformatic support services.

Ginkgo Bioworks has faced challenges to its brand reputation in recent years. In August 2024, discussions compared Ginkgo to Theranos, citing allegations of project failures and stock drops. In November 2021, Ginkgo was sued in a shareholder lawsuit and faced an inquiry by the United States Department of Justice. In March 2023, the former Attorney General of Louisiana launched an investigation into the company's officers and directors. As of 2021, the company reportedly could not name a single significant product manufactured and sold using its organisms.

The ownership structure of Ginkgo Bioworks Holdings, Inc. (DNA) includes institutional, retail, and individual investors. Institutional investors own approximately 45.00% to 59.89% of the stock, with major holders including Viking Global Investors Lp, BlackRock, Inc., and Vanguard Group Inc. Individual and retail investors hold a significant portion, around 22% to 39.15%. Insiders own approximately 0.97% to 17% of the shares, with CEO Jason Kelly owning 3.8%.